Library Subscription: Guest
International Journal of Medicinal Mushrooms

Published 12 issues per year

ISSN Print: 1521-9437

ISSN Online: 1940-4344

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.2 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 1.4 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00066 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.34 SJR: 0.274 SNIP: 0.41 CiteScore™:: 2.8 H-Index: 37

Indexed in

Medicinal Mushroom Substances as Cancer Molecular Therapy

Volume 7, Issue 3, 2005, 352 pages
DOI: 10.1615/IntJMedMushrooms.v7.i3.150
Get accessDownload

ABSTRACT

Medicinal mushrooms possess a variety of health promoting qualities as well as being a potential source of a variety of pharmaceuticals for some diseases, including cancer. Although most of the attention for their anticancer activity revolved around the activity of high-molecular-weight polysaccharides with no clear mechanism of action, our focus is on low-molecular-weight mushroom substances with a well-defined mechanism of action.
A neoplasm is an abnormal mass or colony of cells produced by a relatively autonomous new growth of tissue arising from the clonal expansion of a single cell that has undergone neoplastic transformation, which is usually accompanied by the loss of some specialized functions and the acquisition of new biological properties mediated by alteration in the expression or function of specific molecular targets. Our research interest on mushroom substances that specifically modulate molecular targets implicated in carcinogenesis, especially in chronic myelogenous leukemia (CML) and prostate cancer (PCa).
CML is a malignancy of pluripotent hematopoietic cells characterized by distinctive cytogenetic abnormality resulting in the creation of a p210 Bcr-Abl fusion protein with increased tyrosine kinase activity.
Imatinib is a potent inhibitor of Bcr-Abl and is used as standard therapy for CML. Unfortunately, clinical efficacy continuously decreases with the advancement of the disease. Secondary resistance is mostly due to the acquisition of point mutations in Bcr-Abl, which argues for the need of developing alternative inhibitors of Bcr-Abl.
Medicinal mushrooms exhibiting selective anti-CML activity were selected. Active mushroom substances induced apoptosis and erythroid differentiation in CML cells and caused a reduction in Bcr-Abl levels. Focusing on mushroom #540 and #514, we show that medicinal mushroom substances were effective in inhibiting auto-phosphorylation from wild types as well as from imatinib-resistance mutants of Bcr-Abl.
PCa is the second leading cause of death in Western men. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops into hormone-refractory tumors due to the accumulation of mutations in the androgen receptor (AR) or to the acquisition of alternative cellular pathways that support proliferation and inhibit apoptosis of PCa in androgen-independent mechanisms.
Whereas PCa is very common in Western countries, its levels are very low in several countries in Asia. Several reports linked Eastern diets and cancer occurrence, especially for PCa. Of special interest is the implication of several mushrooms in the prevention of PCa in Asia.
We evaluate the ability of mushroom substances extracted from our collection ot mushroom strains to interfere selectively with the activity of AR, the leading molecular target implicated in the development and maintenance of hormone-refractory PCa. Data showing anti-prostate cancer activity and the ability to modulate AR and other molecular targets will be presented.

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain